Cost-Effectiveness Analysis of Endoscopic Treatment versus Medication Strategy for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease
Digestion · 2024
DOI: 10.1159/000543365 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Digestion, 2024. Verfasst von Fumiaki Ishibashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Proton Pump Inhibitors, Endoscopic Mucosal Resection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Introduction
Potassium-competitive acid blockers are effective against proton pump inhibitor-refractory gastroesophageal reflux disease; however, their long-term use is associated with economic disadvantages. Endoscopic procedures may reduce potassium-competitive acid blocker use. This study aimed to determine the optimal treatment strategy for patients with proton pump inhibitor-refractory gastroesophageal reflux disease from a cost-effectiveness perspective.
Methods
Using a Markov state transition model to simulate symptom changes in patients with proton pump inhibitor-refractory gastroesophageal reflux disease, the cost-effectiveness of two strategies was compared: endoscopic treatment (anti-reflux mucosectomy or endoscopic submucosal dissection for gastroesophageal reflux disease) followed by potassium-competitive acid blocker versus medication with high-dose potassium-competitive acid blocker. In both strategies, potassium-competitive acid blocker maintained symptoms at the lowest controllable dose. The time horizon varied from 10 to 50 years. The quality-adjusted life year and incremental cost-effectiveness ratio were calculated. Willingness to pay was set at 5,000,000 Japanese yen.
Results
The quality-adjusted life years gained were 0.90 and 0.95 for the endoscopic treatment and medication strategies, respectively. The incremental cost-effectiveness ratio varied with the follow-up period after the initial treatment, with the endoscopic treatment strategy being more cost-effective than the medication strategy at ≥50 years of follow-up. A dose reduction success rate of 66.8% were required to determine the superiority of the endoscopic treatment strategy at the 50-year follow-up after treatment.
Conclusions
The endoscopic treatment strategy is not cost-effective unless the patient is followed up for >50 years after the initial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.
- Research and Development Initiative, Chuo University, Tokyo, Japan.
Zitieren
APA
Ishibashi, F., Suzuki, S., Mochida, K., Tonishi, T., & Ishibashi, Y. (2024). Cost-Effectiveness Analysis of Endoscopic Treatment versus Medication Strategy for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Digestion. https://doi.org/10.1159/000543365
Vancouver
Ishibashi F, Suzuki S, Mochida K, Tonishi T, Ishibashi Y. Cost-Effectiveness Analysis of Endoscopic Treatment versus Medication Strategy for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Digestion. 2024. doi:10.1159/000543365
BibTeX
@article{Ishibashi2024,
author = {Ishibashi, Fumiaki and Suzuki, Sho and Mochida, Kentaro and Tonishi, Takao and Ishibashi, Yuichi},
title = {Cost-Effectiveness Analysis of Endoscopic Treatment versus Medication Strategy for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease},
journal = {Digestion},
year = {2024},
doi = {10.1159/000543365}
}
EUVIMED